Pfizer and Astellas Amend Clinical Research Protocols for Two Phase 3 Trials of Enzalutamide in Patients with Hormone-Sensitive Prostate Cancer
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
| Astellas Pharma Inc Unsponsored ADR (AMEX: ALPMY) | Delayed: 15.95 +0.18 (1.14%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $15.77 | 52 Week High | $19.40 | |||
| Open | $15.90 | 52 Week Low | $12.50 | |||
| Day High | $15.99 | P/E | N/A | |||
| Day Low | $15.52 | EPS | $0.00 | |||
| Volume | 95,873 | |||||
| Pfizer Inc. (NYSE: PFE) | Delayed: 30.03 -0.39 (1.28%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $30.42 | 52 Week High | $37.39 | |||
| Open | $30.28 | 52 Week Low | $28.25 | |||
| Day High | $30.32 | P/E | 18.20 | |||
| Day Low | $29.81 | EPS | $1.65 | |||
| Volume | 29,482,896 | |||||
